- Title
- Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas
- Creators
- Jonathan W Friedberg - Jonathan W. Friedberg, Erin Cebula, Richard Burack, and Steven H. Bernstein, University of Rochester Wilmot Cancer Center, Rochester, NY; Daruka Mahadevan, West Clinic and University of Tennessee Health Sciences Center, Memphis, TN; Daniel Persky, Yale University, New Haven, CT; Izidore Lossos, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; Amit G. Agarwal, University of Arizona Cancer Center, Tucson, AZ; and JungAh Jung, Xiaofei Zhou, E. Jane Leonard, Howard Fingert, and Hadi Danaee, Millennium Pharmaceuticals, Cambridge, MADaruka Mahadevan - Jonathan W. Friedberg, Erin Cebula, Richard Burack, and Steven H. Bernstein, University of Rochester Wilmot Cancer Center, Rochester, NY; Daruka Mahadevan, West Clinic and University of Tennessee Health Sciences Center, Memphis, TN; Daniel Persky, Yale University, New Haven, CT; Izidore Lossos, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; Amit G. Agarwal, University of Arizona Cancer Center, Tucson, AZ; and JungAh Jung, Xiaofei Zhou, E. Jane Leonard, Howard Fingert, and Hadi Danaee, Millennium Pharmaceuticals, Cambridge, MAErin Cebula - Jonathan W. Friedberg, Erin Cebula, Richard Burack, and Steven H. Bernstein, University of Rochester Wilmot Cancer Center, Rochester, NY; Daruka Mahadevan, West Clinic and University of Tennessee Health Sciences Center, Memphis, TN; Daniel Persky, Yale University, New Haven, CT; Izidore Lossos, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; Amit G. Agarwal, University of Arizona Cancer Center, Tucson, AZ; and JungAh Jung, Xiaofei Zhou, E. Jane Leonard, Howard Fingert, and Hadi Danaee, Millennium Pharmaceuticals, Cambridge, MADaniel Persky - Jonathan W. Friedberg, Erin Cebula, Richard Burack, and Steven H. Bernstein, University of Rochester Wilmot Cancer Center, Rochester, NY; Daruka Mahadevan, West Clinic and University of Tennessee Health Sciences Center, Memphis, TN; Daniel Persky, Yale University, New Haven, CT; Izidore Lossos, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; Amit G. Agarwal, University of Arizona Cancer Center, Tucson, AZ; and JungAh Jung, Xiaofei Zhou, E. Jane Leonard, Howard Fingert, and Hadi Danaee, Millennium Pharmaceuticals, Cambridge, MAIzidore Lossos - Jonathan W. Friedberg, Erin Cebula, Richard Burack, and Steven H. Bernstein, University of Rochester Wilmot Cancer Center, Rochester, NY; Daruka Mahadevan, West Clinic and University of Tennessee Health Sciences Center, Memphis, TN; Daniel Persky, Yale University, New Haven, CT; Izidore Lossos, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; Amit G. Agarwal, University of Arizona Cancer Center, Tucson, AZ; and JungAh Jung, Xiaofei Zhou, E. Jane Leonard, Howard Fingert, and Hadi Danaee, Millennium Pharmaceuticals, Cambridge, MAAmit B Agarwal - Jonathan W. Friedberg, Erin Cebula, Richard Burack, and Steven H. Bernstein, University of Rochester Wilmot Cancer Center, Rochester, NY; Daruka Mahadevan, West Clinic and University of Tennessee Health Sciences Center, Memphis, TN; Daniel Persky, Yale University, New Haven, CT; Izidore Lossos, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; Amit G. Agarwal, University of Arizona Cancer Center, Tucson, AZ; and JungAh Jung, Xiaofei Zhou, E. Jane Leonard, Howard Fingert, and Hadi Danaee, Millennium Pharmaceuticals, Cambridge, MAJungAh Jung - Jonathan W. Friedberg, Erin Cebula, Richard Burack, and Steven H. Bernstein, University of Rochester Wilmot Cancer Center, Rochester, NY; Daruka Mahadevan, West Clinic and University of Tennessee Health Sciences Center, Memphis, TN; Daniel Persky, Yale University, New Haven, CT; Izidore Lossos, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; Amit G. Agarwal, University of Arizona Cancer Center, Tucson, AZ; and JungAh Jung, Xiaofei Zhou, E. Jane Leonard, Howard Fingert, and Hadi Danaee, Millennium Pharmaceuticals, Cambridge, MARichard Burack - Jonathan W. Friedberg, Erin Cebula, Richard Burack, and Steven H. Bernstein, University of Rochester Wilmot Cancer Center, Rochester, NY; Daruka Mahadevan, West Clinic and University of Tennessee Health Sciences Center, Memphis, TN; Daniel Persky, Yale University, New Haven, CT; Izidore Lossos, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; Amit G. Agarwal, University of Arizona Cancer Center, Tucson, AZ; and JungAh Jung, Xiaofei Zhou, E. Jane Leonard, Howard Fingert, and Hadi Danaee, Millennium Pharmaceuticals, Cambridge, MAXiaofei Zhou - Jonathan W. Friedberg, Erin Cebula, Richard Burack, and Steven H. Bernstein, University of Rochester Wilmot Cancer Center, Rochester, NY; Daruka Mahadevan, West Clinic and University of Tennessee Health Sciences Center, Memphis, TN; Daniel Persky, Yale University, New Haven, CT; Izidore Lossos, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; Amit G. Agarwal, University of Arizona Cancer Center, Tucson, AZ; and JungAh Jung, Xiaofei Zhou, E. Jane Leonard, Howard Fingert, and Hadi Danaee, Millennium Pharmaceuticals, Cambridge, MAE. Jane Leonard - Jonathan W. Friedberg, Erin Cebula, Richard Burack, and Steven H. Bernstein, University of Rochester Wilmot Cancer Center, Rochester, NY; Daruka Mahadevan, West Clinic and University of Tennessee Health Sciences Center, Memphis, TN; Daniel Persky, Yale University, New Haven, CT; Izidore Lossos, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; Amit G. Agarwal, University of Arizona Cancer Center, Tucson, AZ; and JungAh Jung, Xiaofei Zhou, E. Jane Leonard, Howard Fingert, and Hadi Danaee, Millennium Pharmaceuticals, Cambridge, MAHoward Fingert - Jonathan W. Friedberg, Erin Cebula, Richard Burack, and Steven H. Bernstein, University of Rochester Wilmot Cancer Center, Rochester, NY; Daruka Mahadevan, West Clinic and University of Tennessee Health Sciences Center, Memphis, TN; Daniel Persky, Yale University, New Haven, CT; Izidore Lossos, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; Amit G. Agarwal, University of Arizona Cancer Center, Tucson, AZ; and JungAh Jung, Xiaofei Zhou, E. Jane Leonard, Howard Fingert, and Hadi Danaee, Millennium Pharmaceuticals, Cambridge, MAHadi Danaee - Jonathan W. Friedberg, Erin Cebula, Richard Burack, and Steven H. Bernstein, University of Rochester Wilmot Cancer Center, Rochester, NY; Daruka Mahadevan, West Clinic and University of Tennessee Health Sciences Center, Memphis, TN; Daniel Persky, Yale University, New Haven, CT; Izidore Lossos, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; Amit G. Agarwal, University of Arizona Cancer Center, Tucson, AZ; and JungAh Jung, Xiaofei Zhou, E. Jane Leonard, Howard Fingert, and Hadi Danaee, Millennium Pharmaceuticals, Cambridge, MASteven H Bernstein - Jonathan W. Friedberg, Erin Cebula, Richard Burack, and Steven H. Bernstein, University of Rochester Wilmot Cancer Center, Rochester, NY; Daruka Mahadevan, West Clinic and University of Tennessee Health Sciences Center, Memphis, TN; Daniel Persky, Yale University, New Haven, CT; Izidore Lossos, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; Amit G. Agarwal, University of Arizona Cancer Center, Tucson, AZ; and JungAh Jung, Xiaofei Zhou, E. Jane Leonard, Howard Fingert, and Hadi Danaee, Millennium Pharmaceuticals, Cambridge, MA
- Publication Details
- Journal of clinical oncology, Vol.32(1), pp.44-50
- Publisher
- American Society of Clinical Oncology
- Academic Unit
- Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
- Language
- English
- Resource Type
- Journal article
- PMID
- 24043741
- PMCID
- PMC3867644
- Record Identifier
- 991031560959902976
Journal article
Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas
Journal of clinical oncology, Vol.32(1), pp.44-50
2014-01-01
PMCID: PMC3867644
PMID: 24043741
Metrics
19 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.96 Cell Biology
- 1.96.311 Microtubules
- Web Of Science research areas
- Oncology
- ESI research areas
- Clinical Medicine
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites